<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750308</url>
  </required_header>
  <id_info>
    <org_study_id>060198</org_study_id>
    <nct_id>NCT00750308</nct_id>
  </id_info>
  <brief_title>Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi and PE5i</brief_title>
  <official_title>Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will measure the effect of the agent tadalafil on glucose and insulin homeostasis
      in people with metabolic syndrome in the presence and absence of an ACE inhibitor.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Beta Cell Function</measure>
    <time_frame>3 hours</time_frame>
    <description>Beta cell function as measured during a frequently sampled IV glucose tolerance test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>three weeks</time_frame>
    <description>As assessed using IV glucose tolerance test and calculated using Min Mod units mU/mm</description>
  </primary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>tadalafil, ramapril, combo, placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril + tadalafil, washout, placebo+placebo for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ramipril, tadalafil, placebo, combo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combo, placebo, tadalafil, ramipril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, combo, ramipril, tadalafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tadalafil, placebo, ramipril, combo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ramipril, combo, tadalfil, placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combo, ramipril, placebo, tadalafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, tadalafil, combo, ramipril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tadalafil, combo, placebo, ramipril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ramipril, placebo, combo, tadalafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combo, tadalafil, ramipril, placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, ramipril, tadalafil, combo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Ramipril 10 mg per day for three weeks</description>
    <arm_group_label>tadalafil, ramapril, combo, placebo</arm_group_label>
    <arm_group_label>ramipril, tadalafil, placebo, combo</arm_group_label>
    <arm_group_label>combo, placebo, tadalafil, ramipril</arm_group_label>
    <arm_group_label>placebo, combo, ramipril, tadalafil</arm_group_label>
    <arm_group_label>tadalafil, placebo, ramipril, combo</arm_group_label>
    <arm_group_label>ramipril, combo, tadalfil, placebo</arm_group_label>
    <arm_group_label>combo, ramipril, placebo, tadalafil</arm_group_label>
    <arm_group_label>placebo, tadalafil, combo, ramipril</arm_group_label>
    <arm_group_label>tadalafil, combo, placebo, ramipril</arm_group_label>
    <arm_group_label>ramipril, placebo, combo, tadalafil</arm_group_label>
    <arm_group_label>combo, tadalafil, ramipril, placebo</arm_group_label>
    <arm_group_label>placebo, ramipril, tadalafil, combo</arm_group_label>
    <other_name>Altace</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>tadalafil 10 mg every other day for three weeks</description>
    <arm_group_label>tadalafil, ramapril, combo, placebo</arm_group_label>
    <arm_group_label>ramipril, tadalafil, placebo, combo</arm_group_label>
    <arm_group_label>combo, placebo, tadalafil, ramipril</arm_group_label>
    <arm_group_label>placebo, combo, ramipril, tadalafil</arm_group_label>
    <arm_group_label>tadalafil, placebo, ramipril, combo</arm_group_label>
    <arm_group_label>ramipril, combo, tadalfil, placebo</arm_group_label>
    <arm_group_label>combo, ramipril, placebo, tadalafil</arm_group_label>
    <arm_group_label>placebo, tadalafil, combo, ramipril</arm_group_label>
    <arm_group_label>tadalafil, combo, placebo, ramipril</arm_group_label>
    <arm_group_label>ramipril, placebo, combo, tadalafil</arm_group_label>
    <arm_group_label>combo, tadalafil, ramipril, placebo</arm_group_label>
    <arm_group_label>placebo, ramipril, tadalafil, combo</arm_group_label>
    <other_name>Cialis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo matching ramipril</description>
    <arm_group_label>tadalafil, ramapril, combo, placebo</arm_group_label>
    <arm_group_label>ramipril, tadalafil, placebo, combo</arm_group_label>
    <arm_group_label>combo, placebo, tadalafil, ramipril</arm_group_label>
    <arm_group_label>placebo, combo, ramipril, tadalafil</arm_group_label>
    <arm_group_label>tadalafil, placebo, ramipril, combo</arm_group_label>
    <arm_group_label>ramipril, combo, tadalfil, placebo</arm_group_label>
    <arm_group_label>combo, ramipril, placebo, tadalafil</arm_group_label>
    <arm_group_label>placebo, tadalafil, combo, ramipril</arm_group_label>
    <arm_group_label>tadalafil, combo, placebo, ramipril</arm_group_label>
    <arm_group_label>ramipril, placebo, combo, tadalafil</arm_group_label>
    <arm_group_label>combo, tadalafil, ramipril, placebo</arm_group_label>
    <arm_group_label>placebo, ramipril, tadalafil, combo</arm_group_label>
    <other_name>matching ramipril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo matching tadalafil</description>
    <arm_group_label>tadalafil, ramapril, combo, placebo</arm_group_label>
    <arm_group_label>ramipril, tadalafil, placebo, combo</arm_group_label>
    <arm_group_label>combo, placebo, tadalafil, ramipril</arm_group_label>
    <arm_group_label>placebo, combo, ramipril, tadalafil</arm_group_label>
    <arm_group_label>tadalafil, placebo, ramipril, combo</arm_group_label>
    <arm_group_label>ramipril, combo, tadalfil, placebo</arm_group_label>
    <arm_group_label>combo, ramipril, placebo, tadalafil</arm_group_label>
    <arm_group_label>placebo, tadalafil, combo, ramipril</arm_group_label>
    <arm_group_label>tadalafil, combo, placebo, ramipril</arm_group_label>
    <arm_group_label>ramipril, placebo, combo, tadalafil</arm_group_label>
    <arm_group_label>combo, tadalafil, ramipril, placebo</arm_group_label>
    <arm_group_label>placebo, ramipril, tadalafil, combo</arm_group_label>
    <other_name>matching tadalfil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ambulatory subjects, 18 to 70 years of age, inclusive

          2. For female subjects, the following conditions must be met:

               -  Postmenopausal status for at least 1 year,

               -  Status-post surgical sterilization, or

               -  If of childbearing potential, utilization of adequate birth control, and
                  willingness to undergo urine beta-hcg testing prior to drug treatment and on
                  every study day

          3. Metabolic syndrome as defined by 3 or more of the following:

               -  Fasting plasma glucose of at least 100 mg/dL (5.5 mmol/L),

               -  Serum triglycerides of at least 150 mg/dL (1.7 mmol/L),

               -  Serum HDL cholesterol less than 40 mg/dL (1.04 mmol/L) in males and less than
                  50mg/dl (1.30mmol/L) in females,

               -  Blood pressure of at least 130/85 mmHg, or

               -  Waist girth of more than 102 cm in men or 88 cm in women

        Exclusion criteria:

        Subjects presenting with any of the following will not be included in the study:

          1. Diabetes type 1 or type 2, as defined by a fasting glucose of 126 mg/dL or greater or
             the use of anti-diabetic medication

          2. Use of hormone replacement therapy

          3. Statin therapy

          4. In hypertensive subjects, a seated systolic blood pressure greater than 179 mmHg or a
             seated diastolic blood pressure greater than 110 mmHg

          5. Pregnancy

          6. Breast-feeding

          7. Cardiovascular disease such as myocardial infarction within 6 months prior to
             enrollment, presence of angina pectoris, significant arrhythmia, congestive heart
             failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second
             or third degree heart block, mitral valve stenosis, aortic stenosis or hypertrophic
             cardiomyopathy

          8. Treatment with anticoagulants

          9. History of serious neurologic disease such as cerebral hemorrhage, stroke, or
             transient ischemic attack

         10. History or presence of immunological or hematological disorders

         11. Diagnosis of asthma

         12. Clinically significant gastrointestinal impairment that could interfere with drug
             absorption

         13. Impaired hepatic function (aspartate amino transaminase [AST] and/or alanine amino
             transaminase [ALT] &gt; 1.5 x upper limit of normal range)

         14. Impaired renal function (serum creatinine &gt; 1.5 mg/dl)

         15. Hematocrit &lt; 35%

         16. Any underlying or acute disease requiring regular medication which could possibly pose
             a threat to the subject or make implementation of the protocol or interpretation of
             the study results difficult

         17. Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days
             in 1 month)

         18. Treatment with lithium salts

         19. History of alcohol or drug abuse

         20. Treatment with any investigational drug in the 1 month preceding the study

         21. Mental conditions rendering the subject unable to understand the nature, scope and
             possible consequences of the study

         22. Inability to comply with the protocol, e.g. uncooperative attitude, inability to
             return for follow-up visits, and unlikelihood of completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy J Brown, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2008</study_first_posted>
  <results_first_submitted>January 6, 2010</results_first_submitted>
  <results_first_submitted_qc>March 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 12, 2010</results_first_posted>
  <last_update_submitted>December 8, 2014</last_update_submitted>
  <last_update_submitted_qc>December 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Nancy J. Brown</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tadalafil, Ramipril, Combo, Placebo</title>
        </group>
        <group group_id="P2">
          <title>Ramipril, Tadalafil, Placebo, Combo</title>
        </group>
        <group group_id="P3">
          <title>Combo, Placebo, Tadalafil, Ramipril</title>
        </group>
        <group group_id="P4">
          <title>Placebo, Combo, Ramipril, Tadalafil</title>
        </group>
        <group group_id="P5">
          <title>Tadalafil, Placebo, Ramipril, Combo</title>
        </group>
        <group group_id="P6">
          <title>Ramipril, Combo, Tadalafil, Placebo</title>
        </group>
        <group group_id="P7">
          <title>Combo, Ramipril, Placebo, Tadalafil</title>
        </group>
        <group group_id="P8">
          <title>Placebo, Tadalafil, Combo, Ramipril</title>
        </group>
        <group group_id="P9">
          <title>Tadalafil, Combo, Placebo, Ramipril</title>
        </group>
        <group group_id="P10">
          <title>Ramipril, Placebo, Combo, Tadalafil</title>
        </group>
        <group group_id="P11">
          <title>Combo, Tadalafil, Ramipril, Placebo</title>
        </group>
        <group group_id="P12">
          <title>Placebo, Ramipril, Tadalafil, Combo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2">One female withdrew due to muscle pain</participants>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Fourth Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>We provide baseline data for those 18 subjects who completed all four treatment arms and whose data are analyzed in this crossover study.</population>
      <group_list>
        <group group_id="B1">
          <title>Completed Subjects</title>
          <description>Subjects who completed all four treatment arms.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Beta Cell Function</title>
        <description>Beta cell function as measured during a frequently sampled IV glucose tolerance test</description>
        <time_frame>3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placeb Treatment</title>
            <description>Measurements during placebo treatment for all 18 subjects who completed the protocol</description>
          </group>
          <group group_id="O2">
            <title>Ramipril Treatment</title>
            <description>Measurements during ramipril treatment for all 18 subjects who completed the protocol</description>
          </group>
          <group group_id="O3">
            <title>Tadalafil Treatment</title>
            <description>Measurements during tadalafil treatment for all 18 subjects who completed the protocol</description>
          </group>
          <group group_id="O4">
            <title>Combination Treatment</title>
            <description>Measurements during combination (ramipril and tadalafil) for all 18 subjects who completed the protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Beta Cell Function</title>
          <description>Beta cell function as measured during a frequently sampled IV glucose tolerance test</description>
          <units>microU/mM</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.2" spread="45.2"/>
                    <measurement group_id="O2" value="232.3" spread="38.1"/>
                    <measurement group_id="O3" value="292.1" spread="38.9"/>
                    <measurement group_id="O4" value="287.6" spread="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity</title>
        <description>As assessed using IV glucose tolerance test and calculated using Min Mod units mU/mm</description>
        <time_frame>three weeks</time_frame>
        <population>Those who completed protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Treatment</title>
            <description>Measured during placebo treatment in all 18 subjects who completed the study</description>
          </group>
          <group group_id="O2">
            <title>Ramipril Treatment</title>
            <description>Measured during ramipril treatment in all 18 subjects who completed the protocol</description>
          </group>
          <group group_id="O3">
            <title>Tadalafil Treatment</title>
            <description>Measured during tadalafil in all 18 subjects who completed the protocol</description>
          </group>
          <group group_id="O4">
            <title>Combination Treatment</title>
            <description>Measured during combination (ramipril and tadalafil) in all 18 subjects who completed treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>As assessed using IV glucose tolerance test and calculated using Min Mod units mU/mm</description>
          <population>Those who completed protocol</population>
          <units>(mU/L)-1x(min)-1xL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="0.35"/>
                    <measurement group_id="O2" value="1.76" spread="0.34"/>
                    <measurement group_id="O3" value="1.88" spread="0.25"/>
                    <measurement group_id="O4" value="1.76" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Treatment</title>
          <description>Any adverse event that occurred during placebo treatment in anyone who received placebo treatment</description>
        </group>
        <group group_id="E2">
          <title>Ramipril Treatment</title>
          <description>Any adverse event that occured durng ramipril treatment in anyone who received ramipril treatment</description>
        </group>
        <group group_id="E3">
          <title>Tadalafil Tretament</title>
          <description>Any adverse event that occurred during tadalafil treatment in anyone who received tadalafil treatment</description>
        </group>
        <group group_id="E4">
          <title>Combination Treatment</title>
          <description>Any adverse event that occurred during combination (ramipril and tadalafil) treatment in anyone who received combination treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nancy J. Brown</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>615-343-8701</phone>
      <email>nancy.j.brown@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

